Inventor
Wen-Hwa Lee
Inventor
San Diego, CA, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes23%
C07KPeptides20%
C12NMicroorganisms or enzymes17%
G01NInvestigating or analysing materials by determining their chemical or physical properties11%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations7%
A01KAnimal husbandry6%
C07DHeterocyclic compounds6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,793,628Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy202010,730,864RAD51 inhibitors and uses thereof202010,421,753RAD51 inhibitors and uses thereof20199,670,197'Small molecule modifiers of the Hec1-Nek2 interaction in G2/M'20179,422,275'Small molecule modifiers of the HEC1-NEK2 interaction in G2/M'20169,012,455'Pharmaceutical compositions containing an indoyl isoquinoline containing compound and uses thereof'20158,293,764'Compositions and methods for disruption of BRCA2-Rad51 interaction'20128,252,520'Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases'20127,105,156'Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells'20067,060,688'Products and methods for controlling the suppression of the neoplastic phenotype'20066,133,424'ppRB.sup.110 - nuclear phosphoprotein-the retinoblastoma susceptibility gene product'20006,051,396'Method for producing retinoblastoma gene protein products'20005,998,134'Retinoblastoma gene-cancer suppressor and regulator'19995,858,771'Products and methods for controlling the suppression of the neoplastic phenotype'19995,851,991'Therapeutic use of the retinoblastoma susceptibility gene product'19985,821,070'Antibodies reactive with retinoblastoma binding proteins and methods of using same'19985,710,022'Nuclear mitotic phosphoprotein'19985,578,701'ppRB.sup.110 - nuclear phosphoprotein - the retinoblastoma susceptibility gene product'19965,532,220'Genetic mechanisms of tumor suppression'19965,011,773'Human esterase D, its uses and a process of purification'19914,942,123'ppRB.sup.110 -phosphoprotein the retinoblastoma susceptibility gene product'1990Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1990–2020Patents assigned to UNIV CALIFORNIA (16)· patent assignee history
1990–2000Based in San Diego, CA, US· patent location history
1998–2006Patents assigned to CANJI INC (2)· patent assignee history
1998Patents assigned to UNIV TEXAS (2)· patent assignee history
1998–2006Based in San Antonio, TX, US· patent location history
2006–2020Based in Newport Coast, CA, US· patent location history
2012–2015Patents assigned to CHEN PHANG-LANG (3)· patent assignee history
2012–2015Patents assigned to LEE WEN-HWA (3)· patent assignee history
2016–2017Based in Irvine, CA, US· patent location history
2020Based in Taipei, TW· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV CALIFORNIA | 16 | 1990–2020 |
| CHEN PHANG-LANG | 3 | 2012–2015 |
| LEE WEN-HWAself | 3 | 2012–2015 |
| CANJI INC | 2 | 1998–2006 |
| UNIV TEXAS | 2 | 1998 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 8 | 1990–2000 |
| Newport Coast, California, US | 6 | 2006–2020 |
| San Antonio, Texas, US | 4 | 1998–2006 |
| Irvine, California, US | 2 | 2016–2017 |
| Taipei, TW | 1 | 2020 |